Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research

Article preview from "The Gray Sheet" - September 27, 2010

Cross-industry cooperation may be needed to develop more effective bone morphogenetic proteins to promote bone growth and fusion, according to a Medicare advisory panel.

Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research

Article preview from "The Gray Sheet" - September 27, 2010

The Medicare Evidence Development and Coverage Advisory Committee met Sept. 22 at CMS headquarters in Baltimore to weigh in on the agency's next steps on the technology.

While CMS does not have a national coverage analysis open on bone morphogenetic proteins, BMP use has skyrocketed in recent years, with as much as 85% of it off-label (¹ 'The Gray Sheet' Sept. 20, 2010).

The MedCAC panelists said there is not yet enough scientific evidence to support most off-label use of BMP technology, and they came up with detailed recommendations for further research.

By Monica Hogan

To  purchase this article online or get it FREE when you subscribe to "The Gray Sheet".

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512